Table 2.
Immunohistochemical parameters in patients with non-small cell lung cancer
| Marker | Number (%) |
| p53 | |
| Negative | 73 (69.5%) |
| Positive | 32 (30.5%) |
| p16 | |
| Negative | 44 (41.9%) |
| Positive | 61 (58.1%) |
| PCNA | |
| Negative | 60 (57.1%) |
| Positive | 45 (42.9%) |
| p27 | |
| Negative | 61 (58.1%) |
| Positive | 44 (41.9%) |
| Cyclin D1 | |
| Negative | 42 (40.0%) |
| Positive | 63 (60.0%) |
| Rb/p105 | |
| Negative | 59 (56.2%) |
| Positive | 46 (43.8%) |
| Rb2/p130 | |
| Negative | 50 (47.6%) |
| Positive | 55 (52.4%) |
PCNA, proliferating cell nuclear antigen; pRb, retinoblastoma protein.